BioLife Solutions (BLFS) executive sells 418 shares to cover tax withholding

Rhea-AI Filing Summary

BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations, sold 418 shares of common stock in an open-market transaction at $20.74 per share. After this sale, she directly owned 210,665 shares. The sale was executed under a pre-established Rule 10b5-1(c) trading plan adopted to cover tax withholding tied to the vesting of restricted stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster Karen A.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Quality and Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		418	D	$20.74	210,665	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Karen A. Foster	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLife Solutions (BLFS) report for Karen A. Foster?

BioLife Solutions reported that executive Karen A. Foster sold 418 shares of common stock in an open-market transaction at $20.74 per share. This transaction was disclosed on a Form 4 and reflects activity under a pre-arranged Rule 10b5-1 trading plan.

How many BioLife Solutions (BLFS) shares does Karen A. Foster own after this Form 4 sale?

After the reported sale, Karen A. Foster directly owns 210,665 shares of BioLife Solutions common stock. This figure is disclosed in the Form 4 as the total number of shares beneficially owned following the 418-share open-market transaction executed under a Rule 10b5-1 plan.

Was Karen A. Foster’s BioLife Solutions (BLFS) share sale part of a Rule 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted by Karen A. Foster effective February 24, 2022. The footnote explains the plan was established specifically to satisfy tax withholding obligations from restricted stock vesting.

What was the purpose of Karen A. Foster’s BioLife Solutions (BLFS) stock sale?

The footnote states the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock. Using a Rule 10b5-1 trading plan, 418 shares were sold, helping cover tax liabilities that arise when restricted stock awards vest.

What price did Karen A. Foster receive for her sold BioLife Solutions (BLFS) shares?

Karen A. Foster’s 418 sold shares of BioLife Solutions common stock were transacted at $20.74 per share. This per-share sale price is specified directly in the Form 4 transaction details for the open-market sale executed under her Rule 10b5-1 trading plan.